Healthcare
Haw Par Corporation Limited(HAWPY)
Live Price
Offline$53.50
+0.00% today
1Y Change
+86.80%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $3.81B
- Revenue Growth
- -7.6%
- EPS Growth
- +14.6%
- Dividend Yield
- 8.1%
Coverage: 255 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Haw Par Corporation Limited (HAWPY) is a Healthcare stock with a market cap of $3.81B and listed on OTC. The stock last traded around $53.50 and up 86.8% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -7.6%, EPS growth of +14.6%, a dividend yield of 8.1%. What stands out right now is revenue -7.6%, EPS +14.6%, free cash flow +426.3% with operating margin 29.2% and ROIC 1.5%. The dividend matters to the case here, with a current yield around 8.1%. Valuation already assumes a fairly strong business story at P/E 14.4 and price/sales 16.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines HAWPY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-7.6% vs +7.6% peer median
Operating Margin
Above sector median
+29.2% vs +19.4% peer median
P/E
Below sector median
14.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -7.6% and EPS is at +14.6%, with operating margin around 29.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 8.1%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 19, 2026 | โ | +0.0% | +9.1% | +9.1% |
2025 Aug 18, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Apr 23, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HAWPY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HAWPY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HAWPY Max Drawdown
-3.48%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HAWPY and SPY.
Company Overview
Haw Par Corporation Limited
Other OTC
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment invests primarily in quoted securities. In addition, the company owns and leases various investment properties that have lettable area of 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Further, the company provides family and tourist oriented leisure alternatives principally in the form of oceanariums. Haw Par Corporation Limited leases land, building, and office space, as well as offers management support services. The company was incorporated in 1969 and is based in Singapore.
- Leadership
- Ee Lim Wee
- IPO Date
- Apr 3, 2013
- Employees
- 595
- Street Address
- No. 03-03 Haw Par Technocentre
- Mailing
- Singapore, 149598
- Region
- Singapore, SG
- Reporting Currency
- USD
- Investor Line
- 65 6337 9102
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.4
- EV/EBITDA
- 41.7
- Price/Sales
- 16.6
- Price/Book
- 0.9
Growth
- Revenue
- -7.6%
- EPS
- +14.6%
- Free Cash Flow
- +426.3%
Profitability
- Gross Margin
- 56.0%
- Operating Margin
- 29.2%
- Net Margin
- 115.4%
- ROE
- 6.3%
- ROIC
- 1.5%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 7.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.